Building Bayer For The Next Decade And Navigating A Patent Cliff
Bayer's New Head Of Pharma Stefan Oelrich Discusses The Future Of The Company
As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.
You may also be interested in...
Ahead of the German major's fourth-quarter earnings call Feb. 27, analysts at Bernstein have been weighing up Bayer's chances of surviving the patent expiries on Xarelto and Eylea.
As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.